In this review we develop the argument that cholestatic liver diseases, particularly primary biliary cholangitis and primary sclerosing cholangitis (PSC), evolve over time with anatomically an ascending course of the disease process. The first and early lesions are in "downstream" bile ducts. This eventually leads to cholestasis, and this causes bile salt (BS)-mediated toxic injury of the "upstream" liver parenchyma. BS are toxic in high concentration. These concentrations are present in the canalicular network, bile ducts, and gallbladder. Leakage of bile from this network and ducts could be an important driver of toxicity. The liver has a great capacity to adapt to cholestasis, and this may contribute to a variable symptom-poor interval that is often observed. Current trials with drugs that target BS toxicity are effective in only about 50%-60% of primary biliary cholangitis patients, with no effective therapy in PSC. This motivated us to develop and propose a new view on the pathophysiology of primary biliary cholangitis and PSC in the hope that these new drugs can be used more effectively. These views may lead to better stratification of these diseases and to recommendations on a more "tailored" use of the new therapeutic agents that are currently tested in clinical trials. Apical sodium-dependent BS transporter inhibitors that reduce intestinal BS absorption lower the BS load and are best used in cholestatic patients. The effectiveness of BS synthesis-suppressing drugs, such as farnesoid X receptor agonists, is greatest when optimal adaptation is not yet established. By the time cytochrome P450 7A1 expression is reduced these drugs may be less effective. Anti-inflammatory agents are probably most effective in early disease, while drugs that antagonize BS toxicity, such as ursodeoxycholic acid and nor-ursodeoxycholic acid, may be effective at all disease stages. Endoscopic stenting in PSC should be reserved for situations of intercurrent cholestasis and cholangitis, not for cholestasis in end-stage disease. These are arguments to consider a step-wise pathophysiology for these diseases, with therapy adjusted to disease stage. An obstacle in such an approach is that disease stage-defining biomarkers are still lacking. This review is meant to serve as a call to prioritize the development of biomarkers that help to obtain a better stratification of these diseases. (HEPATOLOGY 2017;65:722-738) P harmaceutical innovations and insights into the pathogenesis of a disease do not necessarily develop at parallel speed. In recent years we have seen remarkable progress in understanding the role of nuclear hormone receptors in interorgan and intracellular metabolic signaling. This has led to the initiation of drug development programs with new compounds entering the clinical arena on fast-track programs. However, the necessary progress that should lead to a better stratification and staging of the target diseases has evolved more slowly.
anti-inflammatory drugs for early disease and drugs addressing the consequences of cholestasis (i.e., bile salt [BS] hepatotoxicity) for disease at a later stage. However, in order to apply this more tailored approach, we need a better understanding and reliable biomarkers of the various (time-related) phases and (severity-related) stages of disease.
We propose a new view on the stratification of cholestatic liver diseases as we develop the argument that the pathophysiology in a number of these diseases follows an "ascending" pattern. Usually the lesions start "downstream" in the large or small bile ducts. As the disease follows its course in time the "upstream" canalicular network and liver parenchyma become involved. The terms "downstream" and "upstream" refer to the direction of bile flow and "ascending" refers to lesions spreading from the downstream (bile ducts) to the upstream area (canaliculi and parenchyma) in the liver.
An ascending pattern of pathophysiology is particularly relevant for PBC and PSC and for a number of other cholestatic liver diseases (Table 1) . For other liver diseases one can defend a "descending" course. For instance, in low phospholipid-associated cholelithiasis and progressive familial intrahepatic cholestasis type 3, canalicular phospholipid secretion is impaired. This causes a disturbed balance between BS and phospholipid secretion, and the resulting toxic bile causes bile duct abnormalities downstream of the hepatocytes where the original defect, a mutated phospholipid translocator (ABCB4), is located. (1) Ascending Disease Course PBC and PSC result from necroinflammatory injury of the bile ducts: the interlobular bile ducts and their branches in PBC and the intrahepatic and extrahepatic large bile ducts in PSC, with mostly lymphocytic infiltrates in PBC and mixed lymphocytic and leukocytic infiltrates in PSC. (2) In both diseases, cholangitis may precede overt cholestasis with jaundice by years. Bile duct injury leads to bile leakage and local toxic injury. Thus, although manifest cholestasis with jaundice occurs at a later stage, local BS-mediated bile duct injury likely plays a role already at the time of early bile duct injury.
The liver is known for its capacity for compensatory regeneration after parenchymal injury or cell loss and has numerous mechanisms for adaptation and protection in cholestatic conditions. This may be an underlying reason for the prolonged natural history of cholestatic liver disease. Asymptomatic or symptompoor stages may precede overt cholestasis by years or even decades. If the course of pathology is divided in phases, one can speak of an early inflammatory phase, which is symptom-poor and may go undetected, through a phase of partially successful adaptation that may last many years to a terminal phase of liver cirrhosis with overt cholestasis and progressive portal hypertension. Inflammation prevails in the early phase and toxic injury in the later phase. In PSC these gradual changes may be interrupted by periods of transient cholestasis or cholangitis due to mechanical obstruction of bile flow by fibrotic bile duct strictures. However, when the intercurrent cholestasis is taken care of by temporary stenting, the gradual course of the disease becomes evident.
When a patient presents with symptoms, one has no information on these preceding phases. All one can do is to stage the disease with the available tools. Currently these tools are not optimal as information on the spatial distribution of the lesions throughout the liver is lacking. Information obtained by three-dimensional (3D) reconstruction of histology from a liver biopsy is limited by biopsy size. If it were possible to see a large part of the liver on a 3D microscopic view, one would become aware of areas in the liver with different stage of disease development. Thus, the spatiotemporal progression of disease probably varies in different areas of the liver.
Etiology
A primary immunological cause of both PSC and PBC is supported by the genetic risk architecture of these disorders. (3, 4) There appears to be a strong association with typical immune-related human leukocyte antigen and non-human leukocyte antigen loci encoding cytokine, interferon, and immune regulatory pathways. Genetic risk factors for both PSC and PBC do overlap each other and with other autoimmune disorders such as ulcerative colitis, psoriasis, and rheumatoid arthritis. (3) Of the two main cholestatic liver diseases, PBC qualifies best as an autoimmune disease. Like other autoimmune diseases, PBC predominantly affects women and is associated with other features hinting at an autoimmune background such as vitiligo and Sj€ ogren syndrome. Patients with PBC have antimitochondrial antibodies directed against the E2 subunit of the pyruvate dehydrogenase complex and several other mitochondrial proteins. In PBC, injury of intrahepatic bile ducts is mediated by a necroinflammatory immunemediated process with a dominant role for CD4 1 and CD8 1 T cells. The trigger for activation of the immune system is unknown. Investigators have looked for environmental toxins and viral and bacterial products, but none of these have convincingly been established.
A striking feature of PSC is its association with inflammatory bowel disease (IBD), predominantly ulcerative colitis. Genome-wide association studies indicate linkage disequilibrium of the human leukocyte antigen locus for IBD and PSC. (3, 5) Also, extraintestinal and extrahepatic manifestations such as autoimmune thyroiditis, iridocyclitis, pyoderma, and glomerulonephritis point to autoimmunity. In addition, the intestinal microbiome plays a role in the etiology of IBD with dysbiosis and decreased biodiversity of microbial species. (6) This may play a role in PSC as well. Failure of intestinal barrier function may link IBD and PSC. A leaky gut allows bacterial products to reach the liver and cause inflammation. (7) An important hypothesis is that immune-competent gut- (74, 75) Progressive familial intrahepatic cholestasis type 2 (76, 77) Benign recurrent intrahepatic cholestasis types 1 and 2 (78, 79) Intrahepatic cholestasis of pregnancy (80) (81) (82) Hypercholanemia (NTCP mutation) (83) Genetic Hepatocellular Sepsis Infection Progressive familial intrahepatic cholestasis type 3 (84) Low phospholipid-associated cholelithiasis (1) Genetic Descending 
TOXICITY OF BS
BS are amphipathic molecules that self-associate in aqueous solution to form micelles. (9) At the Na 1 concentration that prevails in body fluids, the critical micellar concentration of the predominant biliary BS ranges from 0.6 to 11 mM. (10) BS levels in concentrated gallbladder bile are typically >50-100 mM, enabling their digestive function in the proximal bowel; in the bile ducts BS levels are in the range 5-10 mM. Like classical detergents, BS in micellar form can disrupt cell membranes. Likewise, monomeric BS can interact with membranes and hydrophobic patches in proteins, thereby interfering with their function.
After injury of bile ducts, BS leak into the surrounding stroma. Depending on their concentration, varying effects have been reported. From preclinical in vitro experiments, it can be deduced that BS at concentrations of 15-25 mM act as signaling molecules, at 50-200 mM they may cause apoptosis, at 200 mM they activate proinflammatory genes, at 200-2,000 mM they induce necrosis, and above 2,000 mM they act as detergents and cause necrosis (Fig. 1) . (11) (12) (13) In bile, conjugated BS are present in phospholipid-containing and cholesterol-containing mixed micelles. In these micelles phospholipids and cholesterol have a neutralizing effect on the inherent cytotoxicity of BS. (14, 15) After an immune-mediated breach of the natural bileblood barrier, the periductular stroma and the basolateral plasma membrane domains of hepatocytes and cholangiocytes are exposed to toxic BS concentrations. These structures are not as resistant to the effect of BS as the sphingomyelin-containing apical domains of hepatocytes and cholangiocytes. (16, 17) This adds (toxic) damage to (immune-mediated) injury and causes periductal inflammation.
Thus, bile leakage can cause local inflammation and bile infarcts, but one may question if BS in hepatocytes ever reach concentrations that are directly toxic. In the human, circulation BS concentrations vary from <1 lM to about 200 lM in cholestasis. (18) In mice, serum BS levels are between 0.5 and 2.3 mM. After bile duct ligation (BDL), the serum concentration rises to levels above 2,000 mM. (19) Taurocholic acid, bmuricholic acid, and tauro-b-muricholic acid are among the most increased BS. A mixture of these three BS, at relevant concentrations, induced inflammatory genes but did not lead to cell death of mouse hepatocytes. (19) Previous studies in humans did not take into account spatiotemporal dynamics and local differences in liver tissue. The ability of hepatocytes to enrich BS in bile canaliculi can lead to much higher local concentrations. We have to conclude that leaks
Concentration-dependent action of BS. Biological activity of BS at various concentrations along the toxicity spectrum (green-red) as well as reported BS levels in humans and mice. (11) (12) (13) 18, 19, 101) from bile ducts or canaliculi are more likely to be a strong contributor to the cause and continuation of cholestatic liver disease than the elevated BS in serum or hepatocytes.
Downstream Events

ADAPTATION OF THE BILIARY TREE
In mice (and humans) the biliary tree can be differentiated into at least three broad topological domains consisting of the large bile ducts running along the portal veins, the interlobular bile ducts that form a mesh around the portal veins, and the canalicular network that borders the hepatocytes (Fig. 2) . To describe the adaptation of the biliary tree in cholestasis, we focus on recently published studies in mice and rats after BDL. It is generally accepted that no single animal model can fully mimic human sclerosing cholangitis. (20) BDL in rodents causes ductular reaction, myofibroblast differentiation of portal fibroblasts, and periportal deposition of extracellular matrix, thereby recapitulating some key features of human PBC. (21) Large bile ducts are defined as having diameters of 100-1,000 mm in mice and include the common bile duct. These respond to obstructive cholestatic stress by enlargement of the ductular diameter through cholangiocyte proliferation. (22, 23) Diametric enlargement increases the capacity of the bile duct to accommodate and conduct biliary fluid.
Further upstream in the biliary tree, interlobular bile ducts, defined as ducts having diameters of 10-15 mm, exist as a mesh of interconnected branching segments that surround the portal vein. In healthy mouse livers the branching frequency of these ducts is approximately 1 in every 100 mm. (23) After BDL, the interlobular ducts undergo extensive remodeling (Fig. 2) . Here, cholangiocyte proliferation initially causes corrugation of the luminal duct surface, leading to an approximately 5-fold increase in surface area, which is further enhanced by additional duct branching, branch elongation, and loop formation through selfjoining while maintaining its proximity to the portal vein. Finally, the relatively sparse ductular mesh surrounding the portal vein becomes approximately 5-fold denser. (23) In contrast to the response of large bile ducts, there is no change in the diameter of interlobular bile ducts following BDL. The number of connections between the interlobular and the lobular bile canalicular network by the canals of Hering decreases proportionally to the increase in lobular bile duct length, suggesting that no novel connections are established. Thus, the remodeling of interlobular bile ducts optimizes the intraluminal surface area by way of corrugation and branching, thereby increasing the cholangiocyte-bile interface and likely facilitating enhanced bile resorption by cholangiocytes. This synergizes with increased apical sodium-dependent BS transporter expression at the apical cholangiocyte membrane, which may lead to more BS reabsorption into cholangiocytes, followed by efflux to the peribiliary plexus by organic solute transporter ab (OSTab) and multidrug resistance-associated protein 3 (Mrp3/MRP3). (24, 25) Consequently, BS concentrations are reduced in the bile duct at the expense of increased blood concentrations. In conclusion, the complex response of the biliary tree after BDL seems to serve different purposes at the distinct topological domains-large bile duct expansion maximizes volume, while increased interlobular bile duct density maximizes surface and thereby bile resorption capacity.
Upstream Events
ADAPTATION OF THE CANALICULAR NETWORK
The final architectural domain of the biliary tree is the canalicular network. To understand the changes that occur in the canalicular network during cholestasis, one has to realize that canaliculi have terminal ends in the central zonal area of the liver lobule that act as a "cul-de-sac." Therefore, the canalicular morphology has to undergo significant changes when bile flow is interrupted by BDL, while the canalicular transporters BS export pump (Bsep) and Mrp2 remain expressed under these conditions. (26) Not only architectural changes are expected and observed but alternative routes for bile efflux need to be in place, to avoid an ever-expanding biliary space. In mice the following is observed: (1) an increase of 30% in average diameter of the canaliculi and (2) increases of 250% in the frequency and of 40% in the length of several spine-like or bleb-like protrusions that intrude into the hepatocyte cytoplasm (Fig. 2) . Alterations in bile canalicular morphology following cholestasis have been known for a long time through electron microscopic data. For instance, cholestatic canaliculi have significantly expanded diameters, as observed more than 50 years ago by electron microscopy (27) and recently by 3D immunostaining and intravital imaging (see Figs. 2  and 3 ). The relevance of these observations remains poorly understood, causes range from increased canalicular pressure to pericanalicular actin and tight junctional remodeling. (21, 28, 29) The observed changes of the canalicular network (Fig. 3A) and leakage of bile (Fig. 3C ) may be explained by disruption of the dynamic coupling between the tight junctional barrier and the periductular cytoskeleton. Knockout of kinase B1, alpha-catenin, or beta-catenin altered canalicular morphology to a widened, tortuous phenotype. Downstream effects of these knockouts range from reduced phosphorylation of adenosine monophosphate-activated protein kinase (30) to disruption of tight-junctional proteins such as Claudin-1 and zona occludens 1 (31) to reduced Wnt signaling activity. (32) The cholestasisinducing drug fasudil inhibits Rho-associated protein kinase and causes dephosphorylation of myosin light chain 2, which leads to dilatation of bile canaliculi of cultured hepatocytes (33) through dysregulation of cortical actin dynamics. When diameters of bile canaliculi increase, vesicles are formed at the apical membrane and released into the cytoplasm, followed by a decrease in canalicular diameter. (34) This builds on the work by Jones et al. and Watanabe et al., who observed regurgitation of immunoglobulin A (IgA) and Na 1 -fluoresceine, respectively, from canaliculi through hepatocytes back to the sinusoids upon increased biliary pressure. (35, 36) Despite the growing knowledge on control mechanisms of bile canalicular morphology, a direct mechanistic link between canalicular pressure and altered bile constituents in cholestasis remains to be uncovered. The a5b1 integrins which bind to and regulate the cortical actin cytoskeleton (37) are directly activated by low micromolar concentrations of tauroursodeoxycholic acid in human sodium-taurocholate contransporting polypeptide (NTCP)-transfected HepG2 cells. (38, 39) Therefore, integrin-mediated stabilization of bile canalicular morphology, in particular the pericanalicular actin cytoskeleton, may represent a target of therapeutic BS.
ADAPTATION OF HEPATOCYTES
Hepatocytes are relatively resistant to BS-mediated toxicity. This is mainly due to protein binding and to altered expression of proteins engaged in synthesis, metabolism, and transport of BS during cholestasis and inflammatory conditions. (25, 26) The adaptive expression in human cholestatic liver is in part mediated by fibroblast growth factor 19 (FGF19, Fgf15 in mice). In healthy persons FGF19 is produced in the terminal ileum by activation of farnesoid X receptor (FXR) by BS. (40) FGF19 in normal human serum follows a diurnal variation as a result of postprandial gallbladder contraction and BS-stimulated activation of FXR in the ileum. (41) During cholestasis, the enterohepatic cycle is interrupted and BS absorption in the ileum and FXR-mediated production of FGF19 are reduced. However, FGF19 in serum of cholestatic patients is elevated. This is due to ectopic FGF19 production in the liver. (42) Thus, in contrast to mouse liver, human liver produces FGF19 during cholestasis. FGF19 binds to its receptor FGFR4, and this causes the down-regulation of cytochrome P450 7A1 (CYP7A1) and attendant repression of de novo BS synthesis. Further adaptations in the cholestatic human liver include down-regulation of uptake transporters and up-regulation of the basolateral efflux transporters (Fig. 4) . (42, 43) In BDL mice and BSEP -/-mice extensive hydroxylation of BS produces tetrahydroxylated BS that can be removed through the urine. (44) These transcriptional and posttranslational changes mainly function to protect hepatocytes against cholestatic injury but not necessarily to protect the biliary tree or the liver against cholestatic injury. For instance, the expression of Mrp2/MRP2 and Bsep/BSEP in mice and humans during cholestasis helps to remove bile acids and other toxic agents from hepatocytes but contributes to a potentially harmful increase of biliary pressure. (26, 42, 43) Bile regurgitation through a   FIG. 4 . Adaptation of transporter and enzyme expression in cholestasis. BS uptake in the liver in humans is mainly mediated by NTCP; in mice organic anion transporting polypeptides (Slco 1a/1b) also play a role (S.F. van de Graaf, 2016, personal comunication); secretion of BS from liver to bile is supported by BSEP. (102, 103) Expression of these proteins is regulated by FXR and FGF19. In humans (and in mice) FGF19 (Fgf15 in mice) is produced in the ileum, (40) but in humans during cholestasis FGF19 is also produced in the liver. This occurs only in humans, not in mice. (42) FGF19 represses CYP7A1 expression. This FGF19-mediated regulation is the mechanism behind the normal diurnal food intake-dependent variation. (41) During cholestasis activation of FXR by elevated BS levels represses CYP7A1 expression in a short heterodimer partner-dependent manner. This causes a significant reduction of de novo BS synthesis with a reduction of C4 in the serum. (104) During cholestasis NTCP and the organic anion transporting polypeptides are down-regulated, while the export transporters canalicular BSEP and basolateral OSTab, MRP3, and MRP4 are up-regulated. (25) During cholestasis the enterohepatic cycling of BS is reduced, and therefore, the BS/FXR-dependent FGF19 synthesis in the ileum is reduced as well. Because of these adaptations, the hepatic concentration of glycochenodeoxycholic acid, the major BS in humans, stays below 100 lM, (18, 101) although local differences may exist. ASBT is the apical sodium-dependent BS transporter in the ileum, and OSTab mediates the transport of BS from ileum to the portal blood. (105, 106) Black lines indicate regulation in normal persons; red lines and arrows indicate regulation during cholestasis. Abbreviations: ATP, adenosine triphosphate; GCDC, glycochenodeoxycholic acid; SHP, short heterodimer partner. paracellular route, leaky tight junctions, or damaged hepatocytes may contribute to reduce biliary pressure. (36, 45) Intravital imaging in mice allows a detailed analysis of bile flow through the various compartments of liver tissue. To examine bile flow in mouse livers after BDL, a bolus of a synthetic fluorescent cholic acid derivative, cholyl-L-lysyl-fluorescein (CLF), was infused through the tail vein and imaged at high acquisition speeds of 1 frame per second. Although CLF is a BS derivative, it is substrate to both BSEP-mediated and MRP2-mediated transport. This dual specificity is probably due to the large fluorescein moiety. (46) Intravital images of cholestatic mouse livers show some extremely wide canaliculi with diameters of up to 10 mm (Fig. 3A, upper panels) . This is in contrast to the picture obtained from fixed tissue, probably due to postmortem changes (Fig. 3B,C; unpublished results) .
Image quantification of intravital videos shows the intensity of CLF in sinusoids, hepatocytes, and FIG. 5 canaliculi and can be used to derive quantitative accretion and depletion rates in these compartments (Fig. 5) . Hepatocytes in normal mice rapidly import CLF from the sinusoids and export it into bile canaliculi and further into the biliary tree ( Fig. 5A,C ; Supporting Video S1). In contrast, after BDL the uptake of CLF from blood into hepatocytes is strongly reduced, while export from hepatocytes into canaliculi occurs at a similar rate as in control mice (Fig. 5B,C ; Supporting Video S2).
These unpublished results are in agreement with the concept that cholestasis leads to down-regulation of uptake transporters and up-regulation of basolateral BS export systems, (47) thereby preventing overloading of hepatocytes with BS.
It is apparent that even under cholestatic conditions the cytoplasmic BS concentrations in mice remain below the apoptotic/necrotic concentrations in most hepatocytes. However, a small number of individual cells that fail to exclude BS was observed (Supporting Video S3). These dispersed cells show delayed CLF uptake, suggesting that their basolateral uptake block is still intact, while enrichment seems to occur through the apical membrane (Fig. 3D, unpublished results) . A similar phenomenon has been observed in BDL rats using Na 1 fluorescein. (36) This excessive "retrograde" (from canaliculus to hepatocyte) CLF leakage is associated with subsequent cell death. Thus, these CLFenriched cells appear to depict a bile infarct of the size of a single hepatocyte. This may indicate a critical originating event in the pathophysiology of cholestatic liver disease. (48) The Role of Intraluminal Biliary Pressure
It has been proposed that hydrostatic pressure after BDL (or other forms of obstructive cholestasis) may contribute to damage of liver tissue. (49) Moreover, increased luminal pressure due to choleretic effects of ursodeoxycholic acid (UDCA) has been postulated to cause rupture of the canals of Hering and consequently bile leaking into the parenchyma, leading to bile infarcts. (49, 50) A recent study indicates that the increased hydrostatic pressure depends on the presence of Bsep as biliary pressure after BDL did not increase in Bsep -/-mice. (44) Disruptions of tight junctions are known to occur throughout the biliary tree, possibly contributing to the leakiness of bile ducts. (51) Leaky bile ducts could allow exchange between the biliary lumen and sinusoidal blood.
However, manometric tracing of biliary pressure revealed increases of only approximately 0.74 mm Hg by BDL and a further increase to 1.0 mm Hg by additional feeding of UDCA to BDL mice, similar to the increase of 2 mm Hg recently reported in BDL Bsep 1/1 wild-type mice. (44, 50) Considering that blood pressure at the basolateral side of hepatocytes is in the range 6-12 mm Hg, it seems unlikely that the relatively small changes in biliary pressure of 1-2 mm Hg can cause direct mechanical tissue damage in this mouse model unless mechanosensing receptors, sensitive enough to detect small changes in pressure, are present where I t is normalized intensity at time t, I 0 is normalized intensity at t50; I max a represents maximum intensity acquired by accretion of CLF, I max a represents total intensity lost by depletion of CLF, t peak is the time at which the intensity of the curve reaches a maximum, and s a and s d are the accretion and depletion time constants, respectively. Fitting of the autocorrelation curves was performed using a 3D anomalous diffusion model. (107) Values are obtained from fits. Error bars indicate 95% confidence intervals. Mice received intravenous injections of 1.0 mg CLF/kg. Unpublished results. Abbreviation: LSEC, liver sinusoidal endothelial cell.
in the biliary tree. (52, 53) A possible alternative mechanism is through a-catenin, which acts as a pressure sensor. (54) Investigations of biliary flow and pressuresensing receptors are in their infancy. Such studies would need to integrate hydrodynamics and highresolution 3D tissue structure with pressure-induced cellular signaling and geometry. A better understanding of biliary fluid dynamics could build on the classic models of fluid homeostasis as approached from an osmotic equilibrium point of view: the M€ unch hypothesis of osmotically driven fluid secretion and flow may also be applicable to bile formation. (55) Therein, the hydrostatic pressure of the fluid opposes the osmotic pressure and limits water inflow and thereby fluid production, representing a form of passive mechanosensing. This mechanism has been studied for epithelial cysts but not applied to bile formation in the liver. (56, 57) On the other hand, cholangiocytes do possess nonmotile primary cilia that actively sense bile tonicity and fluid flow. (58) It is likely that alterations of bile ducts occur through mechanosensation and consequent Ca 21 /cyclic adenosine monophosphate signaling, rather than due to purely physical effects of increased biliary fluid pressure. Other signaling pathways stimulated by BS cause actin and tight junction remodeling that may explain the leakiness of the biliary tree. (28, 29, 59, 60) If biliary pressure plays a role, this will be most relevant for extrahepatic obstruction and PSC, anatomically characterized by bile duct dilatation and beading of the biliary tree. However, despite the evolution of knowledge on possible control mechanisms, a molecular link between either biliary pressure or bile constituents in cholestasis on the periductular cytoskeleton and associated transporter functions has not yet been demonstrated.
Stage-Dependent Biomarkers
Because the etiology of cholestatic liver disease is defined by inflammation and toxic injury, effective therapy should address these two components. These two events cannot be separated in time. However, from the above discussion one can conclude that immune-mediated necroinflammatory damage of the bile ducts probably is a relatively early event, while toxic damage, as a consequence of the inflammatory injury, becomes more important during progression of the disease (Fig. 6) .
Biomarkers to detect early disease are still missing. For detection of early PSC conventional magnetic resonance cholangiography is not sensitive enough and the traditional markers alkaline phosphatase and gamma-glutamyltransferase are indicators of bile duct proliferation and cholestasis rather than inflammation. With careful magnetic resonance cholangiographic analysis or advanced magnetic resonance cholangiography using magnetic resonance contrast agents one may be able to detect early disease. (61) Alkaline phosphatase has been reported to have prognostic value in PSC patients (62) but does not qualify for the detection of early disease. For PBC, imaging is not available and, as in PSC, cholestasis is a sign of advanced disease.
Liver histology is a valuable tool to classify PBC, but its value in PSC is limited as the primary lesions of
Step-wise and ascending pathophysiology.
PSC are to an extent outside the reach of the biopsy needle. Moreover, liver histology is not a tool to detect early disease. The above-described "adaptation phase" may be detected by monitoring serum 7a-hydroxy-4-cholesten-3-one (C4) levels. C4 is BS intermediate and a marker of CYP7A1 activity, the rate-governing enzyme in the conversion of cholesterol to bile salts. (63) As explained above, human liver expresses FGF19 during cholestasis, and this suppresses CYP7A1. (42) In cholestasis, serum C4 levels can be very low. (64) Drugs that further suppress BS synthesis may not be useful in these conditions.
For identification of biomarkers, new roads have to be explored. Because inflammation is an early lesion, alterations of cytokine profiles, including those of tumor necrosis factor-a, interleukins, transforming growth factor-b, and highly sensitive C-reactive protein, may represent candidate biomarkers for early disease. In PSC, interleukin-8 levels in serum and bile are elevated. (65) Serum of PSC patients with biliary strictures showed elevated interleukin 8 when exposed to lipopolysaccharide in vitro. (66) Thus, interleukin 8 might be a candidate biomarker for PSC, but whether it is sensitive enough to be useful in stratification of the disease needs to be explored. Doorenspleet et al. isolated IgG4 1 B-cell receptor clones from plasma of patients with IgG4 cholangitis. (67) Perhaps the isolation of antimitochondrial antibody-positive or perinuclear antineutrophil cytoplasmic antibody-positive B-cell receptor clones could be explored to detect early PBC or PSC.
Pharmacokinetic tests to detect impairment of hepatobiliary secretion, using 11 C-labeled BS derivatives and dynamic positron emission tomographic scanning, (85) TUDCA (86) INT 777 (87) Recommended Abbreviations: ASBT, apical sodium-dependent BS transporter; CCR, chemokine (C-C motif) receptor; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NCT, National Clinical Trial; PPAR, peroxisome proliferator-activated receptor; TNF, tumor necrosis factor; VAP1, vascular adhesion protein 1.
need to be studied in a clinical setting. (68) For staging of biliary strictures in PSC and bile duct lesions in PBC, 3D reconstructions of liver specimens could yield important information.
Stage-Dependent Drug Intervention
For treatment of cholestatic liver disease, drugs or drug combinations should preferably have antiinflammatory and antifibrotic properties and reduce BS toxicity. UDCA is a prototypic BS and serves as a drug that combines these qualities. However, while UDCA has proven beneficial effects in about 60% of PBC patients, it is less effective in PSC. (69) (70) (71) These differences in drug effects may be due to different architectures of the diseases. Both by water efflux following its own secretion and by stimulation of bicarbonate secretion, UDCA causes some degree of choleresis in addition to reducing the viscosity of bile. This hypersecretion is not a problem in PBC, but in PSC, where resistance to biliary outflow is increased, UDCA may increase intrabiliary pressure. Because the portal veins are in close proximity to the biliary tree, in particular the ductular network that forms a mesh around the portal veins, UDCA may augment portal hypertension in selected patients. Data from a Mayo Clinic trial hint at this direction. In a controlled trial PSC patients received high-dose UDCA or placebo. Patients allocated to the UDCA group developed more complications related to portal hypertension than placebo-treated patients. (71) Therefore, drugs that reduce rather than augment biliary pressure are better candidates to treat PSC ( Table 2) .
The outcome of a recent randomized trial on the treatment of PBC with the selective FXR agonist obeticholic acid underscores the argument developed in this review. The drug was given to PBC patients who did not have cirrhosis or jaundice but had an inadequate response to UDCA. Obeticholic acid was effective at lowering serum alkaline phosphatase in 50%-60% of patients with a 10% placebo effect. (72) An earlier study with this compound showed a 40% reduction of alkaline phosphatase in 20% of patients. (73) Stratification on the basis of serum FGF19 and C4 may identify patients with a high probability for response.
In Table 2 we categorize current drugs into agents that address downstream targets (bile ducts) and upstream targets (hepatocytes, canaliculi, Kupffer cells, hepatic stellate cells). It will be clear that there is overlap between these targets. By addressing downstream targets, cholestasis may be reduced or prevented, and this will reduce toxicity at the site of upstream targets. Allocation of drugs into categories that are more useful in early disease stages and those that are more effective in late-stage disease is somewhat theoretical but perhaps useful to underscore the need for a better disease stratification. Because we postulate the concept of an ascending pathophysiology of PBC and PSC, one may speculate that drugs that address downstream targets are more useful in early disease because this is where these diseases are postulated to start. Drugs that address upstream targets include agents that lower the BS load (FXR agonists, BS absorption inhibitors) and drugs that may decrease the load of lipopolysaccharide and toxins from the microbiome.
Conclusions
Immune-mediated necroinflammatory damage of the biliary tree in genetically susceptible individuals is probably the main initiating event in cholestatic liver disease. In PBC these lesions are in the interlobular ducts and ductules, while larger intrahepatic and extrahepatic bile ducts represent sites of primary injury in PSC. The "second hit" is probably toxic in origin and may be mediated by BS in locally high concentrations. The canalicular and ductular network contain BS concentrations high enough to be toxic when they leak into cells in close proximity. Thus, leakage of bile from canaliculi, ductuli, and ducti seems a prerequisite for BS-mediated toxicity to play a role in cholestatic liver disease. BS concentrations in other compartments (e.g., hepatocytes) are simply not high enough.
The question of how "downstream" immunological injury of the biliary tree leads to "upstream" damage of the bile ducts, canaliculi, and liver tissue remains to be resolved. Increased biliary pressure may play a role in PSC and extrahepatic cholestasis, but mechanisms that affect adhesion molecules and junctional complexes may be more important in other cholestatic liver diseases. Elucidation of these mechanisms is important to enable the choice of the correct therapy at the right time and the right stage of disease.
Tools are needed to characterize the stage of disease in individual patients. Methodology to visualize the spatial distribution of disease lesions in 3D throughout the liver is particularly relevant as disease stages may vary in different areas of the liver.
Like in hepatitis B, where an immune-tolerant phase exists wherein therapy is less effective, also in PBC and PSC one may have an adaptation phase wherein further suppression of BS synthesis with FXR agonists may not be effective. In view of an unequal distribution of time-related disease stages, application of the principle of "one-drug-fits-all" may lead to suboptimal responses. Tools need to be developed to study disease stratification, and this then needs to be taken into consideration in designing drug trials.
